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Letter to the Editor 
Diagnostic Genetics
t(12;17)(p13;q12)/TAF15-ZNF384 Rearrangement in 
Acute Lymphoblastic Leukemia
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Department of Laboratory Medicine1, Yonsei University College of Medicine; Department of Pediatrics2, Yonsei Cancer Research Center, Yonsei University 
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Dear Editor,
In ALL, cytogenetic subgroups according to recurrent genetic 
abnormalities are used to classify patients for risk stratification 
and to introduce them to the proper therapeutic strategies—
such as the use of tyrosine kinase inhibitors in the case of 
t(9;22)(q34;q11.2)/BCR-ABL1 fusion [1]. Therefore, the identi-
fication of genetic aberrations is clinically significant and crucial 
in understanding the leukemogenesis mechanisms. 
t(12;17)(p13;q11.2)/TAF15-ZNF384 rearrangement is a rare 
chromosomal abnormality [2]. It has been reported in lymphoid 
as well as myeloid leukemia and is thought to be involved in the 
early differentiation of common progenitors [3]. Although some 
cases of the disease have reported a poor outcome [4, 5], the 
clinical characteristics and prognostic impact of TAF15-ZNF384 
are not well characterized, since not all the previous studies in-
vestigated the precise molecular consequences of the translo-
cation. We report a B-ALL case with t(12;17)(p13;q11.2) de-
tected by cytogenetic analysis and confirmed by direct se-
quencing of the TAF15-ZNF384 transcripts, which substanti-
ated genes involved in the rearrangement. 
A 32-month-old girl was admitted following four days of fever 
and erythema of both legs. Initial complete blood counts dem-
onstrated pancytopenia, with hemoglobin level of 5.5 g/dL, 
white blood cell counts of 2.63×109/L, and platelet counts of 
123×109/L. Leukemic blasts up to 5% were observed in pe-
ripheral blood and 84.9% in bone marrow. The leukemic blasts 
varied in size, with scanty and occasionally granulated cyto-
plasms. Blasts were positive for CD34, CD19, CD13, CD33, cy-
toplasmic CD79a, and terminal deoxynucleotidyl transferase 
(TdT), and negative for CD2, CD7, CD10, CD14, myeloperoxi-
dase, and cytoplasmic CD3, indicating pro-B cell stage ALL. 
The reverse transcription-polymerase chain reaction using the 
HemaVision kit (DNA technology, Aarhus, Denmark) and fluo-
rescence in situ hybridization using Vysis IGH/MYC/CEP8 tri-
color dual fusion, CDKN2A (p16)/CEP9 dual spot, and MLL 
Break Apart probes (Abbott Molecular, Abbott Park, IL, USA) 
showed negative results. G(Giemsa)-T(Trypsin)-G-banding anal-
ysis using the bone marrow sample revealed a karyotype of 
46,XX,t(12;17)(p13;q11.2)[8]/46,XX[11] (Fig. 1A). To confirm 
the TAF15-ZNF384 fusion transcript, complementary DNA was 
synthesized from total RNA, amplified, and sequenced by using 
primers specific for TAF15 and ZNF384 [6]. The fusion tran-
script, amplified by using specific primers, was approximately 
800 bp in length (Fig. 1B). Sequence alignment of the amplified 
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Table 1.  Summary of acute leukemia cases with the TAF15-ZNF384 fusion transcript confirmed by molecular studies
Reference
Sex/Age 
(yr)
Extramedullary 
involvement
Initial 
WBC 
(×109/L)
Immunophenotype Diagnosis Treatment
Follow-up 
(month)
La Starza R, et al. [5] M/24 No 22.9 HLA-DR+, CD34+, CD13+, CD19+, CD22+, TdT+ Pro-B ALL aBMT 2 CR 89+
La Starza R, et al. [5] F/44 No 2.9 HLA-DR+, CD34+, CD13+, CD33+, CD19+, 
CD22+, CD79a+, TdT+
Pro-B ALL BMT 1 CR 60+
La Starza R, et al. [5] F/16 No 30.4 HLA-DR+, CD34+, CD13+, CD19+, CD22+, CD45+ Pro-B ALL BMT 2 CR 49+
La Starza R, et al. [5] F/26 Spleen 4.8 HLA-DR+, CD34+, CD19+, sCD22+,TdT+ Pro-B ALL BMT 1 CR 44+
La Starza R, et al. [5] M/7 No 7.2  HLA-DR+, CD34+, CD33+, CD19+, CD22+, 
CD24+, cCD79A+, CD10+, TdT+
Pro-B ALL 1 CR 33+
La Starza R, et al. [5] M/29 No 65.6 CD13+, CD33+, CD19+ AML (M1) CHT relapse 8d
Nyquist KB, et al. [6] M/19 No 92 HLA-DR+, CD34+, CD19+, CD22+, CD38+,CD45+, 
CD58+, CD123+, CD10+, TdT+
Pro-B ALL 1 CR 27+
Nyquist KB, et al. [6] F/3 NA 36.5 HLA-DR+, CD33+, CD19+, CD22+, cCD79a+, 
CD10+, TdT+
Pro-B ALL HR relapse 96d
Grammatico S, et al. [3] F/25 No 3.1 CD34+, CD33+, CD19+, CD22+ Pro-B ALL HR relapse 34d
This study F/2 No 2.6 CD34+, CD13+, CD33+, CD19+, cCD79a+, TdT+ Pro-B ALL 1 CR 8+
Abbreviations: WBC, white blood cells; aBMT, autologous bone marrow transplantation; BMT, allogeneic bone marrow transplantation; CR, complete 
remission; CHT, standard chemotherapy; HR, high-risk chemotherapy; d, died; +, alive; NA, not available.   
Fig. 1. (A) G(Giemsa)-T(Trypsin)-G-banding analysis using the bone marrow sample revealed a translocation involving the breakpoint on 
chromosome 12p13 and 17q11.2. (B) Agarose gel electrophoresis of the TAF15-ZNF384 fusion transcript obtained from patient (approxi-
mately 800-bp-sized PCR product) (C) Direct sequencing of complementary DNA showed breakpoints between exon 9 of TAF15 and exon 
3 of ZNF384. Lane L, bp markers; Lane Pat, reported patient with TAF15-ZNF384 fusion transcript. 
12 der(12) 17 der(17)
100C
800
600
500
400
300
200
100
A B
C
TAF15 exon9 INF384 exon3
Kim J, et al.
B-ALL with t(12;17)(p13;q12)
398  www.annlabmed.org http://dx.doi.org/10.3343/alm.2016.36.4.396
product revealed breakpoints between exon 9 of TAF15 and 
exon 3 of ZNF384 (Fig. 1C).
Diagnostic lumbar puncture and computed tomography ruled 
out the central nervous system (CNS) involvement. She achieved 
complete remission by day 35 following a single course of stan-
dard risk induction chemotherapy, including cytarabine, metho-
trexate, vincristine, hydrocortisone, and I-asparaginase. Thereaf-
ter, she received high-dose cyclophosphamide consolidation and 
intrathecal methotrexate CNS prophylaxis, followed by high-risk 
vincristine and methotrexate maintenance, and has been in re-
mission for eight months after the initial diagnosis. 
The t(12;17)(p13;q11), t(12;17)(p13;q12), or t(12;17)(p11-
12;q11-12), for which the breakpoint assignment differs slightly, 
was first described in 1982 by Kaneko et al. [7]. Its molecular 
fusion gene, TAF15-ZNF384, was shown to be involved in tu-
morigenesis in 2002 [2]. To the best of our knowledge, there 
have been 10 cases of TAF15-ZNF384 fusion confirmed using 
molecular studies (Table 1). In addition to the early B-cell mor-
phology, coexpression of myeloid markers and a lack of expres-
sion of CD10 are common immunophenotypic features of this 
entity [8]. There are conflicting reports regarding the prognosis 
of cases with t(12;17) [3, 5, 6]. Owing to its low incidence, the 
treatment protocol differs between institutions, and the statisti-
cal significance of t(12;17) in terms of clinical outcome has not 
been analyzed to date [3]. Studies with a larger ALL patient 
group displaying such changes are required in order to deter-
mine the prognostic impact of TAF15-ZNF384 fusion. 
Primers and probes for TAF15-ZNF384 are not usually in-
cluded in commercial kits for screening leukemia translocations, 
so this abnormality may be missed in routine clinical settings. 
We suggest that special attention be paid when a translocation 
between 12p13 and 17q11 is suspected and that additional 
studies for TAF15-ZNF384 may be useful in ALL diagnoses. In-
cluding this fusion transcript in the initial screening panel can 
assist in identifying underdiagnosed cases and distinguishing 
ambiguity of t(12;17), therefore establishing their incidence and 
clinical significance.
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